CIK: 0001560009
Total reported value
$141.4M
Reporting period: 2026-03-31 · Number of holdings: 8
Versant Venture Management, LLC disclosed 8 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $141.4M and a quarterly turnover rate of 45.4%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "V"
Versant Venture Management, LLC's disclosed holdings carry a Herfindahl concentration index of 0.232 — mathematically equivalent to about 4 equally-sized positions, well below its 8 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.99), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward initiating meaningfully larger new positions than it adds to existing ones (a 19.4 percentage-point tilt) — a pattern consistent with a more contrarian, new-idea-driven approach.
Sector classification currently covers about 5% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim LENZ
0.0% -$18.2M
Trim GLUE
-27.4% -$16.4M
Add CTNM
0.0% $884.5K
Trim JBIO
0.0% -$2.1M
Trim OVASUSD
0.0% -$331.8K
Trim CRSP
0.0% -$724.8K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 37.00% | -8.49% | -27.42% | |
| 2 | IPSC | Century Therapeutics INC | Stock-Other | 19.44% | +19.44% | NEW | |
| 3 | LENZ | Lenz Therapeutics INC | Stock-Other | 17.19% | -10.95% | — | |
| 4 | JBIO | Jade Biosciences INC | Stock-Other | 15.16% | -0.43% | — | |
| 5 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 5.01% | +0.90% | — | |
| 6 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 5.01% | -0.16% | — | |
| 7 | SKYE | Skye Bioscience INC | Stock-Other | 0.87% | -0.13% | — | |
| 8 | OVASUSD | Tempest Therapeutics INC | Stock-Other | 0.31% | -0.20% | — |
Performance for Q3 2026
+11%
Performance Last 4 Quarters
+172.8%
Based on 58% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 8 | $141.4M | 45 | |
| 2025-12-31 | 7 | $151.1M | 75 | |
| 2025-09-30 | 9 | $212.5M | 100 | |
| 2025-06-30 | 8 | $82.1M | 0 | |
| 2025-03-31 | 7 | $60.2M | 100 | |
| 2024-12-31 | 7 | $86.7M | 0 | |
| 2024-09-30 | 6 | $63.6M | 0 | |
| 2024-06-30 | 8 | $77.3M | 0 | |
| 2024-03-31 | 7 | $103.1M | 0 | |
| 2023-12-31 | 7 | $388.8M | 0 | |
| 2023-09-30 | 8 | $188.1M | 0 | |
| 2023-06-30 | 8 | $84.3M | 0 | |
| 2023-03-31 | 7 | $48.0M | 0 | |
| 2022-12-31 | 7 | $48.3M | 0 | |
| 2022-09-30 | 8 | $58.7M | 0 | |
| 2022-06-30 | 8 | $65.2M | 0 | |
| 2022-03-31 | 10 | $100.2M | 0 | |
| 2021-12-31 | 10 | $187.0M | 0 | |
| 2021-09-30 | 11 | $241.5M | 0 | |
| 2021-06-30 | 11 | $301.8M | 100 | |
| 2021-03-31 | 11 | $513.3M | 92 | |
| 2020-12-31 | 12 | $963.0M | 72 | |
| 2020-09-30 | 11 | $546.4M | 38 | |
| 2020-06-30 | 12 | $696.1M | 64 | |
| 2020-03-31 | 9 | $364.6M | 65 | |
| 2019-12-31 | 7 | $331.8M | 37 | |
| 2019-09-30 | 8 | $258.5M | 28 | |
| 2019-06-30 | 9 | $343.2M | 40 | |
| 2019-03-31 | 9 | $303.6M | 44 | |
| 2018-12-31 | 10 | $202.0M | 46 | |
| 2018-09-30 | 10 | $294.0M | 33 | |
| 2018-06-30 | 9 | $320.5M | 7 | |
| 2018-03-31 | 8 | $312.7M | 100 | |
| 2017-12-31 | 7 | $95.0M | 40 | |
| 2017-09-30 | 8 | $131.4M | 28 | |
| 2017-06-30 | 8 | $127.1M | 26 | |
| 2017-03-31 | 8 | $137.5M | 37 | |
| 2016-12-31 | 7 | $102.7M | 24 | |
| 2016-09-30 | 7 | $89.7M | 100 | |
| 2016-06-30 | 5 | $98.7M | 75 | |
| 2016-03-31 | 7 | $138.5M | 26 | |
| 2015-12-31 | 7 | $170.9M | 37 | |
| 2015-09-30 | 7 | $174.4M | 96 | |
| 2015-06-30 | 5 | $78.8M | 52 | |
| 2015-03-31 | 6 | $113.7M | 30 | |
| 2014-12-31 | 5 | $104.6M | — |
Versant Venture Management, LLC's most significant position changes for 2026-03-31: New buy: Century Therapeutics INC (IPSC); Trim: Monte Rosa Therapeutics INC (GLUE) — shares -27.42%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CTNM | Contineum Therapeutics Inc-a | +0.9% | — | Unchanged |
| 2 | SKYE | Skye Bioscience INC | -0.1% | — | Unchanged |
| 3 | CRSP | CRISPR Therapeutics AG | -0.2% | — | Unchanged |
| 4 | OVASUSD | Tempest Therapeutics INC | -0.2% | — | Unchanged |
| 5 | JBIO | Jade Biosciences INC | -0.4% | — | Unchanged |
| 6 | GLUE | Monte Rosa Therapeutics INC | -8.5% | -27.42% | Trim |
| 7 | LENZ | Lenz Therapeutics INC | -11% | — | Unchanged |
| 8 | IPSC | Century Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-05 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-12 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-10 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-11 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-07 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-12 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-08 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-07 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-03 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-08 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-03 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-09 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-11 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-09 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-10 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-11 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-10 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-11 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-12 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-12 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-07 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-12 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-07-20 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-04-28 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-01-21 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-10-08 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-07-12 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-04-05 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-01-22 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-10-05 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-07-13 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-03 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-01-25 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-10-13 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-02 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-04-07 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-01-18 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-10-24 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-07-28 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-04-25 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-05-05 | Amendment | View on EDGAR |
| 2015-12-31 | 2016-02-10 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-10-28 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-07-15 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-04-23 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-04-23 | Amendment | View on EDGAR |
| 2014-12-31 | 2015-04-22 | Amendment | View on EDGAR |
| 2014-12-31 | 2015-04-02 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001094584
Total reported value
$141.4M
504 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002044675
Total reported value
$141.4M
93 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0000927628
Total reported value
$141.4M
91 stks
2022-03-31
Stale — no recent filing
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001201001
Total reported value
$100.9M
5 stks
2026-03-31
1 of the top 5 holdings overlap, including Century Therapeutics INC
CIK 0001274413
Total reported value
$120.7M
77 stks
2026-03-31
1 of the top 5 holdings overlap, including Contineum Therapeutics Inc-a
CIK 0001558858
Total reported value
$790.5M
20 stks
2026-03-31
1 of the top 5 holdings overlap, including Lenz Therapeutics INC